Source-defined biomarker
Surrogate endpoint used to assess the clinical endpoints of hip and non-vertebral fracture risk reduction
This exact source name has not been reconciled to a broader biomarker identity.
Surrogate endpoint used to assess the clinical endpoints of hip and non-vertebral fracture risk reduction is a source-defined biomarker in the evidence tier "FDA qualification project". This page lists evidence by type: FDA biomarker qualification projects (1), each linked to its source.
Source-scoped identity
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
FDA qualification project
An FDA Biomarker Qualification Program project names this biomarker.
Source-level evidence only
Gene-level evidence mining does not apply to this kind of biomarker, so the source assertions on this page are the full depth available for it. A section missing below was not measured, and does not mean zero evidence.
FDA biomarker qualification projects (1)
Shown in this order: most recent snapshot first.
| Project | DDT number | Source status | Submitter | Biomarker role |
|---|---|---|---|---|
| Surrogate endpoint used to assess the clinical endpoints of hip and non-vertebral fracture risk reduction | DDT-BMQ-000054 | FDA-qualified | FNIH-ASBMR SABRE | Not assigned |
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions and assay-provider ledger.